Smart missile drug takes aim at Hard-to-Treat prostate cancer

NCT ID NCT07657806

Not yet recruiting Disease control Sponsor: Hangzhou DAC Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called DEC003M, which is designed to seek out and destroy prostate cancer cells by targeting a protein called PSMA. The trial enrolls adults with advanced prostate cancer that has stopped responding to standard hormone therapy. Researchers aim to find the safest dose and check whether the drug can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DEC003M (an antibody drug conjugate targeting PSMA)
What this could lead to: If successful, this could lead to a new treatment option for advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is an early phase 1 trial with a small number of participants, so the drug may not prove effective or may have unexpected side effects. It is too early to know if it will benefit patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER

Contacts and locations

Locations

Chongqing University Cancer Hospital

Chongqing, 400030, China
The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 311121, China
The Third People's Hospital of Chengdu

Chengdu, Sichuan, 610095, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.